Peter Powchik, MD


Peter has been associated with Vaxxinity and United Neuroscience since 2018. His expertise includes clinical development, translational medicine, and building research organizations. Prior to joining United Neuroscience he was SVP Head of Clinical Development at Regeneron Pharmaceuticals from 2006-2018 where he oversaw the development and approval of Regeneron’s first seven drugs and helped build its development and regulatory infrastructure. He is also formerly EVP of Clinical Development, Chugai USA; VP of Clinical Development and Medical Affairs, US at Novartis overseeing the development and approval of Ritalin LA and Focalin; and Senior Director at Sepracor where he initiated the development of Lunesta. He is a board certified psychiatrist having trained at NYU School of Medicine, Mt Sinai Medical Center (NYC), and Columbia University College of Physicians and Surgeons.